NCT06413082

Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment

Pharmacogenetics of Hypertension: a Single-centre Randomized Study in Patients With Essential Hypertension Treated With Spironolactone or Torasemide

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 38 (actual)
• Sponsor: Ospedale San Raffaele · Academic / Other
• Sex: All
• Age: 25 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Phase III interventional study to evaluate the different efficacy of Torasemide and Spironolactone in reducing systolic blood pressure in carriers and non-carriers of the different genotypic combinations for Lanosterol and Uromodulin

Detailed description

The investigators will enroll 144 naïve hypertensive subjects who will undertake 2-4 weeks of run-in and 4 weeks of treatment (7 day window at each visit). During this period partecipants will follow a low sodium diet (about 5g/day) and will be monitored with blood chemistry tests

Conditions

• Hypertension
• Genetic Predisposition
• Drug Effect

Interventions

Type	Name	Description
DRUG	Torasemide	The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups
DRUG	Spironolactone	The assignment to each drug will be carried out randomly in each genotypic group with the aim of reaching the same number of patients treated with the two drugs in the different genotypic groups

Timeline

• Start date: 2021-02-15
• Primary completion: 2023-07-07
• Completion: 2023-09-03
• First posted: 2024-05-14
• Last updated: 2024-05-16

Locations

2 sites across 1 country: Italy